Products with Hepatoprotective bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1088 | Saikosaponin D |
| Saikosaponin D, a calcium mobilizing agent (SERCA inhibitor), is also an agonist of the glucocorticoid receptor (GR),which has anti-cancer, anti-inflammatory, and neuroprotective effects. Saikosaponin D protects against acetaminophen-induced hepatotoxicity by inhibiting NF-κB and STAT3 signaling; it shows inhibitory effects on NF-κB activation and thereby on iNOS, COX-2 and pro-inflammatory cytokines. | |
| BCN1112 | Rhoifolin |
| Rhoifolin possesses a variety of significant biological activities including antioxidant, anti-inflammatory, antimicrobial, hepatoprotective and anticancer effects, it may be beneficial for diabetic complications through its enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and GLUT4 translocation. Rhoifolin has a radioprotective effect against radiation-induced decrease of blood platelets and cardiac biochemical lesions in whole body irradiated mice. | |
| BCN1116 | Swertiamarin |
| Swertiamarin possesses anti-hyperglycemic, anti-hyperlipidemic, anti-diabetic activity and enhances β cell regeneration which causes reversal of diabetes. Swertiamarin also possesses significant wound healing, anti-inflammatory, antioxidant, hepatoprotective, peripheral and central antinociceptive properties. Swertiamarin inhibits the development of arthritis by modulating NF-κB/IκB and JAK2/STAT3 signaling, it acts as an anti-rheumatic agent. | |
| BCN1136 | Myricitrin |
| Myricitrin exhibits hepatoprotective, anti-inflammatory,antioxidant, anti-allergic, antinociception, anxiolytic-like, and antipsychotic-like effects. Myricitrin can be used as a drug candidate for the treatment of cardiovascular diseases, by effectively protecting cells from ox-LDL-induced endothelial cell apoptosis and reducing atherosclerotic plaque formation. Myricitrin is also a nitric oxide (NO) and protein kinase C (PKC) inhibitor that has central nervous system activity. | |
| BCN1153 | Loganin |
| Loganin is a non-competitive inhibitor of BACE1 with IC50 of 47.97 μM an also inhibits AChE and BChE with IC50 values of 3.95 μM and 33.02 μM, respectively. Loganin has neuroprotective, anti-amnesic, anti-inflammatory and anti-shock effects, it also exhibits protective effects against hepatic injury and other diabetic complications associated with abnormal metabolic states and inflammation caused by oxidative stress and advanced glycation endproduct formation. Loganin can attenuate neuroinflammatory responses through the inactivation of NF-κB by NF-κB dependent inflammatory pathways and phosphorylation of MAPK in Aβ25-35-induced PC12 cells, and can protect against hydrogen peroxide-induced apoptosis by inhibiting phosphorylation of JNK, p38, and ERK 1/2 MAPKs in SH-SY5Y cells. | |
